Steven Jon  Russell net worth and biography

Steven Russell Biography and Net Worth

Insider of Beta Bionics

Dr. Russell is an endocrinologist and diabetologist with nearly 20 years of experience managing diabetes. He is an Associate Professor of Medicine at Harvard Medical School and an attending physician at the Massachusetts General Hospital (MGH) Diabetes Associates where he maintains a part-time clinical practice managing diabetes in the outpatient and inpatient settings. Dr. Russell’s research has been focused on the application of new technologies to improve the care of people with diabetes, including the collaboration with Dr. Ed Damiano’s research group at Boston University to develop and test a wearable bionic pancreas for automated blood glucose control in diabetes. Dr. Russell has directed nearly all of the bionic pancreas clinical trials, amounting to approximately 20 inpatient and home-use studies in type 1 diabetes, type 2 diabetes and cystic fibrosis related diabetes. He received a Bachelor of Science degree in biochemistry from Trinity University in San Antonio, and both a PhD in biological chemistry and an MD from the University of Texas Southwestern Medical Center. He completed both his residency training in internal medicine and his endocrinology fellowship at MGH, and a postdoctoral fellowship studying insulin and aging at the Joslin Diabetes Center.

What is Steven Jon Russell's net worth?

The estimated net worth of Steven Jon Russell is at least $2.18 million as of September 2nd, 2025. Russell owns 71,017 shares of Beta Bionics stock worth more than $2,177,381 as of December 4th. This net worth estimate does not reflect any other assets that Russell may own. Learn More about Steven Jon Russell's net worth.

How do I contact Steven Jon Russell?

The corporate mailing address for Russell and other Beta Bionics executives is 11 HUGHES, IRVINE, CA, 92618. Beta Bionics can also be reached via phone at (949) 427-7785 and via email at [email protected]. Learn More on Steven Jon Russell's contact information.

Has Steven Jon Russell been buying or selling shares of Beta Bionics?

Steven Jon Russell has not been actively trading shares of Beta Bionics during the past quarter. Most recently, Steven Jon Russell sold 1,015 shares of the business's stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $18.86, for a transaction totalling $19,142.90. Following the completion of the sale, the insider now directly owns 71,017 shares of the company's stock, valued at $1,339,380.62. Learn More on Steven Jon Russell's trading history.

Who are Beta Bionics' active insiders?

Beta Bionics' insider roster includes Stephen Feider (CFO), Mark Hopman (Insider), Mike Mensinger (Insider), and Steven Russell (Insider). Learn More on Beta Bionics' active insiders.

Are insiders buying or selling shares of Beta Bionics?

In the last twelve months, Beta Bionics insiders bought shares 2 times. They purchased a total of 1,033,350 shares worth more than $17,566,950.00. In the last twelve months, insiders at the sold shares 18 times. They sold a total of 76,232 shares worth more than $1,471,002.63. The most recent insider tranaction occured on October, 31st when Director Adam Lezack sold 1,406 shares worth more than $37,779.22. Learn More about insider trades at Beta Bionics.

Information on this page was last updated on 10/31/2025.

Steven Jon Russell Insider Trading History at Beta Bionics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/2/2025Sell1,015$18.86$19,142.9071,017View SEC Filing Icon  
6/2/2025Sell1,039$17.89$18,587.7172,032View SEC Filing Icon  
See Full Table

Steven Jon Russell Buying and Selling Activity at Beta Bionics

This chart shows Steven Jon Russell's buying and selling at Beta Bionics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Beta Bionics Company Overview

Beta Bionics logo
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Read More

Today's Range

Now: $30.00
Low: $29.56
High: $31.51

50 Day Range

MA: $25.15
Low: $19.53
High: $31.51

2 Week Range

Now: $30.00
Low: $8.89
High: $32.71

Volume

2,652,084 shs

Average Volume

474,329 shs

Market Capitalization

$1.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A